This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Chemokine CXC motif ligand 10 (CXCL10; IP-10)	<p><i>In vitro</i> and mouse studies suggest antibodies targeting CXCL10 could help treat breast cancer. In human breast cancer tissue samples, $\gamma\delta T_{reg}$ cells, which suppress antitumor immunity, accumulated in tumors but not in healthy tissue. In mice bearing subcutaneous human breast tumors and adoptively transferred human $\gamma\delta T_{reg}$ cells, a CXCL10-neutralizing antibody prevented tumor $\gamma\delta T_{reg}$ cell accumulation and decreased tumor growth compared with an isotype control antibody. Next steps could include testing antibodies against CXCL10 in additional breast cancer models.</p> <p>Bristol-Myers Squibb Co.'s MDX-1100, a mAb targeting CXCL10, is in Phase II testing to treat inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). NovImmune S.A.'s CXCL10 mAb, NI-0801, is in Phase II testing for liver disease and cirrhosis.</p> <p>SciBX 6(38); doi:10.1038/scibx.2013.1055 Published online Oct. 3, 2013</p>	Patent and licensing status unavailable	<p>Ye, J. <i>et al. Cancer Res.</i>; published online Aug. 19, 2013; doi:10.1158/0008-5472.CAN-13-0348 Contact: Guangyong Peng, Saint Louis University, St. Louis, Mo. e-mail: gpeng@slu.edu</p>